David Hipkiss, CEO of Prosonix, recently spoke to CHEM-anager Europe about the company's endeavours in using its proprietary sonocrystallization and particle engineering technologies for Making Better Medicines. Within this discussion David spoke at length about the application of proprietary pharmaceutical ultrasonic particle engineering technologies, ultrasonic process chemistry and processing equipment to deliver sustainable value to the pharmaceutical industry.

He also mentions the use of multidisciplinary approaches to solve the complex solid-state problems of pharmaceuticals and fine chemicals clients. To read more about David's view of this emerging niche market of pharmaceutical particle engineering and sonocrystallization, and the developments of the company within the current business climate please refer to the link below.

http://www.chemanager-online.com/en/topics/pharma-biotech-processing/making-better-medicines